Comments on: UBS Equity Analyst States That Sale Of Biogen Idec (BIIB) Is “Foregone Conclusion”: To Whom And At What Price The Question

Comments on: UBS Equity Analyst States That Sale Of Biogen Idec (BIIB) Is “Foregone Conclusion”: To Whom And At What Price The Question http://www.twst.com/blog/2009/10/24/ubs-equity-analyst-states-that-sale-of-biogen-idec-biib-is-foregone-conclusion-to-whom-and-at-what-price-the-question/ Inside the world of Professional Investors and Company Management hourly 1 http://wordpress.org/?v=3.0